Natera Inc
NASDAQ:NTRA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Natera Inc
NASDAQ:NTRA
|
US |
|
Storskogen Group AB (publ)
STO:STOR B
|
SE |
|
Les Hotels de Paris SA
PAR:HDP
|
FR |
|
Amicus Therapeutics Inc
NASDAQ:FOLD
|
US |
|
Dolly Varden Silver Corp
XTSX:DV
|
CA |
|
E
|
Empresas Copec SA
SGO:COPEC
|
CL |
|
H
|
Hanger Inc
F:HO8
|
US |
|
Forian Inc
NASDAQ:FORA
|
US |
|
A
|
Almondz Global Securities Ltd
NSE:ALMONDZ
|
IN |
Natera Inc
In the dynamic world of biotechnology, Natera Inc. stands out as a leader in genetic testing and diagnostics. Founded with the vision of transforming how we understand our genetic blueprint, Natera has grown into a significant player, leveraging advanced molecular biology to decode human DNA with remarkable precision. The company's flagship technology, a proprietary cell-free DNA platform, underpins an array of genetic tests that cater to diverse needs in the fields of oncology, women's health, and organ health. Through this technology, Natera offers prenatal screening tests like Panorama, which can detect chromosomal abnormalities early in pregnancy, providing crucial insights for expectant parents. Additionally, the company's oncology solutions, such as Signatera, assist in tailoring personalized cancer treatment regimens by detecting minimal residual disease, thereby offering oncologists a powerful tool for disease management.
Financially, Natera sustains its operations through a robust business model that combines direct billing and reimbursements from insurance providers, alongside partnerships with healthcare institutions. By offering innovative testing solutions, Natera generates revenue through test processing fees and related services. The company's growth is fueled by its investments in research and development, constantly pushing the boundaries to enhance test accuracy and expand into new markets. This strategic focus has not only broadened its portfolio but also fortified its ties with healthcare professionals and institutions worldwide. In navigating the complex landscape of genetic science, Natera continues to play a pivotal role in advancing personalized medicine, positioning itself as a linchpin in the future of healthcare diagnostics.
In the dynamic world of biotechnology, Natera Inc. stands out as a leader in genetic testing and diagnostics. Founded with the vision of transforming how we understand our genetic blueprint, Natera has grown into a significant player, leveraging advanced molecular biology to decode human DNA with remarkable precision. The company's flagship technology, a proprietary cell-free DNA platform, underpins an array of genetic tests that cater to diverse needs in the fields of oncology, women's health, and organ health. Through this technology, Natera offers prenatal screening tests like Panorama, which can detect chromosomal abnormalities early in pregnancy, providing crucial insights for expectant parents. Additionally, the company's oncology solutions, such as Signatera, assist in tailoring personalized cancer treatment regimens by detecting minimal residual disease, thereby offering oncologists a powerful tool for disease management.
Financially, Natera sustains its operations through a robust business model that combines direct billing and reimbursements from insurance providers, alongside partnerships with healthcare institutions. By offering innovative testing solutions, Natera generates revenue through test processing fees and related services. The company's growth is fueled by its investments in research and development, constantly pushing the boundaries to enhance test accuracy and expand into new markets. This strategic focus has not only broadened its portfolio but also fortified its ties with healthcare professionals and institutions worldwide. In navigating the complex landscape of genetic science, Natera continues to play a pivotal role in advancing personalized medicine, positioning itself as a linchpin in the future of healthcare diagnostics.
Record Revenue Growth: Natera reported Q4 revenue of approximately $666 million, marking about 40% growth over Q4 2024 and exceeding January preannounced figures by $6 million.
Strong Volume Expansion: The company processed about 924,000 tests in Q4, including a record 225,000 MRD clinical tests—a 56% year-over-year increase.
Gross Margin Upside: Gross margin reached 66.9% in Q4, significantly higher than expectations, with organic gross margin (excluding true-ups) at 63.7%.
Cash Flow & Profitability: Natera generated over $107 million in cash flow for 2025 and achieved net income in Q4, aided by a one-time tax item.
2026 Guidance Initiated: Revenue for 2026 is guided between $2.62 billion and $2.7 billion with gross margins expected between 63% and 65%. SG&A will be held stable while R&D investment increases.
Product & Clinical Advancements: New launches and data in MRD, women's health (notably the 21-gene fetal focus NIPT test), and organ health are driving growth and opening new market opportunities.
Margin & ASP Drivers: Continued improvements in ASP, operational efficiencies, and broader reimbursement are expected to drive further margin expansion.
